{"id":"W4220847549","doi":"10.1136/jitc-2021-004233","title":"Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; Pharmacyclics; Genentech; PharmaMar; Eisai; Syndax Pharmaceuticals; Clovis Oncology; BeiGene; Conquer Cancer Foundation; Merck KGaA; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Princess Margaret Cancer Foundation; Pfizer; Mersana Therapeutics","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Immunotherapy; Cabozantinib; Clinical endpoint; Endometrial cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Cancer; Clinical trial; Gastroenterology; Phases of clinical research; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003773009,0.002131569,0.0027324,0.0004776528,0.0005813875,0.001331821,0.001078089,0.001968179,0.007982899],"category_scores_gemma":[0.002895598,0.0008221239,0.00193816,0.0005553307,0.00178612,0.001181237,0.000599743,0.003438664,0.001229467],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001746192,"about_ca_system_score_gemma":0.00289289,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001468327,"about_ca_topic_score_gemma":0.004373215,"domain_scores_codex":[0.9988039,0.0008007291,0.00005014528,0.000146284,0.00006019408,0.0001387964],"domain_scores_gemma":[0.9984504,0.00031306,0.0004336838,0.0001722583,0.0001183958,0.0005121055],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9782039,0.006814078,0.0007131044,0.000486683,0.0008870167,0.00003833738,0.00005705833,0.0003467149,0.002136745,0.0001264319,0.001097458,0.009092341],"study_design_scores_gemma":[0.9450896,0.05215827,0.0009801477,0.00002620657,0.0002741031,0.00003350421,0.0000217153,0.0002542671,0.0002035796,0.0002112537,0.000739503,0.000007815749],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9678555,0.007704169,0.001109624,0.00244829,0.0009869968,0.01430346,0.002137356,0.0001688619,0.00328567],"genre_scores_gemma":[0.9706796,0.003053813,0.002805932,0.002319106,0.0007370816,0.01395728,0.002367177,0.00003571829,0.004044332],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007982899,"threshold_uncertainty_score":0.0267055,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04021511302289515,"score_gpt":0.3943897692277361,"score_spread":0.354174656204841,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}